More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

布鲁顿酪氨酸激酶 伊布替尼 CD8型 外周血单个核细胞 免疫学 免疫系统 T细胞 癌症研究 酪氨酸激酶 慢性淋巴细胞白血病 细胞毒性T细胞 B细胞 医学 生物 受体 白血病 抗体 内科学 体外 生物化学
作者
Chia Sharpe,Joanne E. Davis,Kylie D. Mason,Dale I. Godfrey,Adam P. Uldrich,Constantine S. Tam,Rachel Koldej,David Ritchie
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 4417-4417 被引量:3
标识
DOI:10.1182/blood-2018-99-117618
摘要

Abstract Background: Chronic lymphocytic leukaemia (CLL) is associated with profound immune dysfunction, which is often exacerbated by CLL therapies. This study aimed to understand the impact of multiple BTK inhibitors on the function of cytotoxic T cells. BTK, along with ITK, TXK, BMX and TEC is a member of the Tec family of nonreceptor tyrosine kinases which are integral to the downstream signalling of many immune receptors. Critically, BTK and ITK are downstream of the B cell and T cell receptors. Whilst identified as a selective BTK inhibitor, ibrutinib inhibits all five members of the Tec family at clinically meaningful doses (Long et al, JCI, 2017). More selective BTK inhibitors have been developed, including acalabrutinib and zanubrutinib, which have less affinity for ITK but variable inhibition for other Tec family members. Functional impairment of NK cells by ibrutinib is well established (Kohrt et al, Blood 2014), however the effects on T cell function remains unclear. It has been suggested that inhibiting ITK results in skewing of CD4 T cells toward a T helper 1 phenotype whilst CD8 T cell function is preserved due to redundant kinase signalling (Dubovsky et al, Blood, 2013). This is yet to be demonstrated in patients and little is known about the impact of BTK inhibitors on cytotoxic T cell populations. Methods: Peripheral blood mononuclear cells were isolated from CLL patients receiving either ibrutinib or zanubrutinib and from treatment naive CLL patients or age matched healthy donors. T cell proliferation was measured using CellTrace Violet, cultures of whole PBMC were stimulated with CD3/CD28 beads and 20 IU/mL IL-2 and treated with 1uM ibrutinib or zanubrutinib or acalabrutinib or vehicle control for 7 days, n=7. CD8 T cell and NKT cell degranulation in response to CD3/CD28 stimulation was assessed using CD107a mobilisation and IFN𝛾 production over 4 hours, n=6 and n=7. Whole PBMC from patients treated with either ibrutinib or zanubrutinib were stimulated for 24 hours using CD3/CD28 beads, supernatants were analysed using a BD™ Cytometric Bead Array. Results: In vitro treatment with ibrutinib significantly impairs the function of cytotoxic T cells. Both CD4 and CD8 T cells cultured in the presence of ibrutinib had significantly decreased proliferation, whilst zanubrutinib and acalabrutinib did not significantly impact T cell proliferation (Figure 1, p=0.0002 and p<0.0001). Furthermore, CD8 T cells from CLL patients and healthy donors had significant abrogation of degranulation and cytokine production when treated with Ibrutinib but not the more selective BTK inhibitors. Similarly, ibrutinib treated healthy donor NKT cells showed significantly diminished degranulation and IFN𝛾 production (Figure 2, p =0.0004 and p=0.0003). Finally, PBMC isolated from patients after treatment with ibrutinib had muted cytokine production including IL-2 (p= 0.003), IL-17A (p=0.023), TNF (p=0.031) and IL-10 (p=0.016) as compared to PBMC isolated before ibrutinib treatment. However there was no significant change in Th1 or Th2 cytokines. Discussion: Together these results highlight the impact of Ibrutinib on cell mediated cytotoxicity. In both in vitro and ex vivo functional assays ibrutinib, but not more selective BTK inhibitors perturbed proper T cell function. Whilst CD4 T cell proliferation was suppressed Th1 skewing was not observed in ibrutinib treated patients. Furthermore. CD8 T cells had profoundly impaired responses to TCR stimulation. Understanding how BTK inhibitors alter the function of cytotoxic cells is essential for the combination of these therapies with immunotherapies and may inform the use of these therapies in the context of adoptive cellular therapies and transplantation. Disclosures Tam: Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
null完成签到,获得积分10
刚刚
1秒前
阳光的梦寒完成签到 ,获得积分10
1秒前
magicjerry完成签到,获得积分10
1秒前
meng发布了新的文献求助10
1秒前
2秒前
冷艳紫南完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
嚣张的豆豆完成签到,获得积分10
3秒前
酷波er应助ljl采纳,获得10
3秒前
Hello应助墨客采纳,获得10
4秒前
量子星尘发布了新的文献求助10
4秒前
完美世界应助Jiancui采纳,获得10
4秒前
zzbyxh发布了新的文献求助10
5秒前
聪慧的从雪完成签到 ,获得积分10
5秒前
5秒前
5秒前
fornas完成签到,获得积分10
6秒前
王1完成签到,获得积分20
6秒前
6秒前
7秒前
火星上初翠完成签到,获得积分10
7秒前
7秒前
7秒前
小酥肉完成签到,获得积分10
7秒前
ChenYX发布了新的文献求助30
7秒前
,,,完成签到,获得积分10
8秒前
9秒前
9秒前
英俊的铭应助难过千易采纳,获得10
10秒前
10秒前
Chemistry发布了新的文献求助10
11秒前
Craig发布了新的文献求助20
11秒前
14秒前
15秒前
原子发布了新的文献求助10
15秒前
情怀应助朱之欣采纳,获得10
16秒前
昵称有敏感词完成签到,获得积分10
16秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975250
求助须知:如何正确求助?哪些是违规求助? 3519625
关于积分的说明 11199055
捐赠科研通 3255962
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877358
科研通“疑难数据库(出版商)”最低求助积分说明 806298